These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 23747732

  • 1. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
    Ahn S, Lee IH, Lee E, Kim H, Kim YC, Jon S.
    J Control Release; 2013 Sep 10; 170(2):226-32. PubMed ID: 23747732
    [Abstract] [Full Text] [Related]

  • 2. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM.
    Regul Pept; 2007 Jun 07; 141(1-3):113-9. PubMed ID: 17292977
    [Abstract] [Full Text] [Related]

  • 3. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo.
    Nguyen HN, Wey SP, Juang JH, Sonaje K, Ho YC, Chuang EY, Hsu CW, Yen TC, Lin KJ, Sung HW.
    Biomaterials; 2011 Apr 07; 32(10):2673-82. PubMed ID: 21256586
    [Abstract] [Full Text] [Related]

  • 4. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC.
    J Control Release; 2009 Feb 10; 133(3):172-7. PubMed ID: 18977255
    [Abstract] [Full Text] [Related]

  • 5. A novel approach to oral delivery of insulin by conjugating with low molecular weight chitosan.
    Lee E, Lee J, Jon S.
    Bioconjug Chem; 2010 Oct 20; 21(10):1720-3. PubMed ID: 20849099
    [Abstract] [Full Text] [Related]

  • 6. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
    Kim D, Jeon H, Ahn S, Choi WI, Kim S, Jon S.
    J Control Release; 2017 Jun 28; 256():114-120. PubMed ID: 28457895
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
    Chuang EY, Nguyen GT, Su FY, Lin KJ, Chen CT, Mi FL, Yen TC, Juang JH, Sung HW.
    Biomaterials; 2013 Oct 28; 34(32):7994-8001. PubMed ID: 23891516
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.
    Lee J, Lee C, Kim TH, Lee ES, Shin BS, Chi SC, Park ES, Lee KC, Youn YS.
    J Control Release; 2012 Aug 10; 161(3):728-34. PubMed ID: 22634071
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA.
    Int J Pharm; 2008 May 22; 356(1-2):231-8. PubMed ID: 18291606
    [Abstract] [Full Text] [Related]

  • 12. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
    Gao W, Jusko WJ.
    Drug Metab Dispos; 2012 May 22; 40(5):990-7. PubMed ID: 22338110
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M, Muñoz-Garach A, Tinahones FJ.
    Expert Opin Drug Metab Toxicol; 2018 Feb 22; 14(2):207-217. PubMed ID: 29260924
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
    Kim I, Kim TH, Ma K, Lee ES, Kim D, Oh KT, Lee DH, Lee KC, Youn YS.
    Bioconjug Chem; 2010 Aug 18; 21(8):1513-9. PubMed ID: 20715855
    [Abstract] [Full Text] [Related]

  • 15. Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.
    Kwon KC, Nityanandam R, New JS, Daniell H.
    Plant Biotechnol J; 2013 Jan 18; 11(1):77-86. PubMed ID: 23078126
    [Abstract] [Full Text] [Related]

  • 16. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
    Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, Watada H.
    Biochem Biophys Res Commun; 2009 Dec 18; 390(3):809-14. PubMed ID: 19836346
    [Abstract] [Full Text] [Related]

  • 17. Low molecular weight chitosan-based conjugates for efficient Rhein oral delivery: synthesis, characterization, and pharmacokinetics.
    Luo J, Sun J, Luo X, Wei Y, Zheng H, Mu C, Yao W.
    Drug Dev Ind Pharm; 2019 Jan 18; 45(1):96-104. PubMed ID: 30196732
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
    Lim SM, Eom HN, Jiang HH, Sohn M, Lee KC.
    J Pharm Sci; 2015 Jan 18; 104(1):72-80. PubMed ID: 25407390
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.
    Rydén A, Nyman G, Nalin L, Andreasson S, Velikyan I, Korsgren O, Eriksson O, Jensen-Waern M.
    Nucl Med Biol; 2016 Jul 18; 43(7):397-402. PubMed ID: 27179248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.